|
HOMOZYGOUS VARIEGATE PORPHYRIA
HOMOZYGOTES AND COMPOUND
HETEROZYGOTES
Variegate
porphyria (VP) is an autosomal dominant
condition. As such, patients carry a single
mutated allele for the protoporphyrinogen
oxidase (PPOX) enzyme, inherited from
the carrier parent, alongside a normal
allele from the normal parent (See Inheritance
of porphyria). Very rarely patients
are found to have inherited a mutated
allele from both parents. If the mutation
on both alleles is identical, such patients
are homozygotes. If the two mutations
are not the same, they are compound heterozygotes.
Potentially such patients
are very much worse affected than heterozygotes.
Typically they show some or all of the
following features:
- Onset of photosensitivity in infancy,
rather than after puberty.
- Severe skin changes with photomutilation.
- Developmental abnormalities in bone:
short, abnormal fingers are characteristic.
Some of this may be due to photo-osteolysis,
but there appears to be a developmental
aspect as well with disproportionate
growth failure in the more distal extremities.
- Sensory neuropathy.
- Neurodevelopmental abnormalities.
- Epilepsy.
Interestingly, surprisingly
and completely unexplained, they do not
appear to be at increased risk of acute
attacks. We have diagnosed four such patients
in the South African population (this
contrasts with about 50 000 patients carrying
typical, heterozygous VP). Two are sisters.
The three families are apparently unrelated,
and, the two sisters are from a mixed-race
family. All the families must however
be distantly relatedpotentially
as far back as 1688since they carry
the South African founder R59W mutation.
Approximately a further 10 patients have
been identified elsewhere in the world.
SEVERITY
The
severity depends on the mutations. The
mutant enzyme protein produced by at least
one of the mutated alleles must express
some residual biochemical activity, otherwise
the resulting complete haem deficiency
is incompatible with life. The greater
the residual activity (another way of
saying the less severe the mutation),
the more benign the clinical effects (See
Mutations
in the PPOX gene in South African families).
This is well seen in the South African
patients shown in the accompanying illustration.
The young patient in the top frame carries
the R59W mutation as well as another fairly
severe mutation; the patient in the bottom
frame carries the R59W mutation in addition
to a second, less severe mutation. You
will notice that her hands are much less
severely affected.
Despite
the frequency of the R59W mutation in
South Africa. We have never encountered
a true homozygote. The reason is simple:
the R59W mutation completely abolishes
enzyme activity and a homozygous fetus
would not survive. Prof Meissner of our
Centre has good experimental evidence
for this: using genetic techniques, he
has developed a strain of mouse carrying
the R59W mutation in its own PPOX gene,
and has shown that when two carriers are
mated, the growth of the homozygous fetuses
are severely retarded and they die in
utero at an early stage. See the accompanying
figure.
OTHER HOMOZYGOUS PORPHYRIAS
The other autosomal dominant
porphyrias: acute
intermittent porphyria, hereditary
coproporphyria and porphyria
cutanea tarda, have all been described
in the homozygous or compound heterozygous
state. Fewer than 5-10 such individuals
are known for each porphyria.
Two of the porphyrias,
congenital erythropoietic porphyria and
ALA dehydratase porphyria (See Unusual
forms of porphyria), are recessive
conditions and are found only in homozygotes
or compound heterozygotes, and are therefore
also extremely rare.
Erythropoietic protoporphyria
Eythropoietic
protoporphyria is interesting. Recent
work has shown that only those who inherit
a mutation on one allele plus a polymorphism
which is common in general European populations
on the other allele, and which leads to
slightly reduced expression of that otherwise
normal gene, show clinical symptoms. Such
patients are not usually considered as
compound heterozygotes since the polymorphism
is so common among normal people, being
found in about 11% of European populations,
including the white population of South
Africa. This probably accounts for the
fact that EPP is considerably more common
than other "homozygous" porphyrias,
and for the fact that we have only seen
in it in the white population in South
Africa.
Back
to top of page
|